Resources to empower the addiction treatment workforce
This webpage contains guidance, resources, and news from around the country regarding addiction treatment in the wake of COVID-19.
Pharmacy Access Survey
The Pharmacy Access Survey Report uses data collected from ASAM’s Pharmacy Access Survey. This survey collected self-reported data from close to 200 respondents between February 2020 and September 2022. Respondents represent 32 different states. The implications of this survey data will be used to inform ASAM’s response to addressing pharmacy access issues and ensuring that all evidence-based medications for opioid use disorder, including buprenorphine, are readily available to those who need treatment.
Learn more about the qualifications for and process to apply for a buprenorphine waiver, as well as resources ASAM has to help members increase their patient limit.